Latest Hotspot

Genascence Corp. begins Phase 1b trial for knee arthritis gene therapy GNSC-001

9 January 2024
3 min read

Genascence Corporation, an innovative biotech entity at the clinical phase, is transforming the management of widespread musculoskeletal conditions using gene therapeutic methods. The company has recently declared the commencement of its early-stage Phase 1b clinical study, employing their novel treatment, GNSC-001, specifically targeting the alleviation of symptoms in patients afflicted with knee osteoarthritis.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Recruitment for the investigation is currently underway at a network of ten clinical study sites across the U.S. Around 50 subjects are expected to join the trial, which is anticipated to reach full enrollment by the beginning of 2024.

GNSC-001 represents a novel genetic therapeutic approach – it is a recombinant adeno-associated virus (AAV) vector engineered to express an enhanced version of IL-1Ra, a protein that naturally inhibits the activity of interleukin-1 (IL-1). IL-1 plays a crucial role in the development of osteoarthritis (OA), contributing to inflammation, pain in the joints, and damage to cartilage. GNSC-001 aims to deliver persistent suppression of IL-1 with a single injection directly into the joint affected by OA.

"Individuals with osteoarthritis experience debilitating long-term pain and impaired mobility, yet we currently lack therapies that can slow down the progression of the disease," stated Thomas Chalberg, Ph.D., the innovator behind Genascence and its CEO. "Our team is thrilled to see the Phase 1B DONATELLO trial actively progressing in ten locations nationwide, marking an important move forward in developing the first gene-based treatment for widespread diseases such as OA."

"The GNSC-001 gene therapy holds promise to revolutionize how OA is treated," remarked Lachy McLean, M.D., Ph.D., and chief medical officer at Genascence. "We are eager to unveil the preliminary data from the DONATELLO study by the end of 2024 and to continue propelling our clinical efforts to deliver this innovative treatment solution to patients with the utmost urgency."

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of January 9, 2024, there are 54 investigational drugs for the IL1R1 target, including 63 indications, 54 R&D institutions involved, with related clinical trials reaching 237, and as many as 4775 patents.

GNSC-001 is an AAV-based gene therapy that targets IL1R1 for the treatment of skin and musculoskeletal diseases, specifically osteoarthritis of the knee. It is currently in Phase 1 of clinical development, focusing on safety and dosage evaluation. The drug's mechanism of action involves delivering a therapeutic gene that produces IL-1Ra, an antagonist to IL1R1, to reduce inflammation. 

图形用户界面, 文本, 应用程序

描述已自动生成

Deciphering H1 receptor antagonists and Keeping Up with Their Recent Developments
Deciphering H1 receptor antagonists and Keeping Up with Their Recent Developments
9 January 2024
H1 receptor antagonists are drugs that block histamine action, relieving allergic reactions. The future holds potential for advancements in treating allergic and inflammatory disorders.
Read →
Upstream Bio begins Phase II trial for Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps, treating first patients
Latest Hotspot
3 min read
Upstream Bio begins Phase II trial for Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps, treating first patients
9 January 2024
Upstream Bio has initiated the first patient treatments in a Phase II study on Verekitug (UPB-101) targeting Chronic Rhinosinusitis with Nasal Polyps.
Read →
Biological Glossary | What is Specific Region?
Bio Sequence
2 min read
Biological Glossary | What is Specific Region?
9 January 2024
In biology, a specific region typically refers to a specific area within a biological context, such as a particular area on a gene, chromosome, protein, or cell.
Read →
Ventus Therapeutics starts trials on VENT-03, a drug to inhibit cGAS, a novel strategy in its class
Latest Hotspot
3 min read
Ventus Therapeutics starts trials on VENT-03, a drug to inhibit cGAS, a novel strategy in its class
9 January 2024
Ventus Therapeutics has begun trials on VENT-03, an oral drug designed to block cGAS, marking a pioneering approach in this category.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.